Jiaxin Tran, MD
Physical Medicine & Rehabilitation · Lincoln, NENPI 1710205042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 28.4% of the total. 2025 is the largest year on record at $422, 2.8 times the $148 reported in 2019.
Across 70 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$442
- Ipsen Biopharmaceuticals, Inc$250
- Coloplast$155
- Johnson & Johnson$145
- Merz Pharmaceuticals, LLC$138
- Piramal Critical Care$63
- plus $364 from 12 others
What the payments were for
- Food & beverage$1,557100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $442 |
| Ipsen Biopharmaceuticals, Inc | 10 | $250 |
| Coloplast | 8 | $155 |
| Johnson & Johnson | 4 | $145 |
| Merz Pharmaceuticals, LLC | 5 | $138 |
| Piramal Critical Care | 3 | $63 |
| Amneal Pharmaceuticals LLC | 2 | $54 |
| Dynasplint Systems Inc. | 1 | $51 |
| Medtronic | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 3 | $40 |
| Merz North America, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Lifeward, Inc. | 1 | $19 |
| Metacel Pharmaceuticals LLC | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
How this compares
$1,557 in reported general payments places this provider in the 85th percentile of 57 physical medicine & rehabilitation providers in Nebraska.
See all physical medicine & rehabilitation providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 12 | $2,120 |
| Baclofen | 71 | $2,049 |
| Gabapentin | 55 | $740 |
| Quetiapine Fumarate | 24 | $439 |
| Pregabalin | 17 | $435 |
| Clonazepam | 20 | $301 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $294 |
| Atorvastatin Calcium | 27 | $287 |
| Hydroxychloroquine Sulfate | 13 | $185 |
| Solifenacin Succinate | 13 | $164 |
| Finasteride | 11 | $151 |
| Tizanidine Hcl | 11 | $145 |
| Amitriptyline Hcl | 19 | $133 |
| Oxycodone Hcl | 14 | $125 |
| Famotidine | 15 | $113 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Lincoln
- David DiamantLincoln$2K
- Adam KafkaLincoln$2K
- Paul KrabbenhoftLincoln$1K
- Morgan LaholtLincoln$836
- Megan HaringLincoln$301
- Joseph MulkaLincoln$119
- Rhondel McCannLincoln$38
- Kurt GoldOmaha$8K
- Daniel WikColumbus$8K
- Jeremy GallantOmaha$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.